These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

245 related items for PubMed ID: 10197613

  • 1. Cremophor EL-mediated alteration of paclitaxel distribution in human blood: clinical pharmacokinetic implications.
    Sparreboom A, van Zuylen L, Brouwer E, Loos WJ, de Bruijn P, Gelderblom H, Pillay M, Nooter K, Stoter G, Verweij J.
    Cancer Res; 1999 Apr 01; 59(7):1454-7. PubMed ID: 10197613
    [Abstract] [Full Text] [Related]

  • 2. Influence of Cremophor El on the bioavailability of intraperitoneal paclitaxel.
    Gelderblom H, Verweij J, van Zomeren DM, Buijs D, Ouwens L, Nooter K, Stoter G, Sparreboom A.
    Clin Cancer Res; 2002 Apr 01; 8(4):1237-41. PubMed ID: 11948138
    [Abstract] [Full Text] [Related]

  • 3. Pharmacokinetic modeling of paclitaxel encapsulation in Cremophor EL micelles.
    van Zuylen L, Karlsson MO, Verweij J, Brouwer E, de Bruijn P, Nooter K, Stoter G, Sparreboom A.
    Cancer Chemother Pharmacol; 2001 Apr 01; 47(4):309-18. PubMed ID: 11345647
    [Abstract] [Full Text] [Related]

  • 4. Disposition of Cremophor EL in humans limits the potential for modulation of the multidrug resistance phenotype in vivo.
    Sparreboom A, Verweij J, van der Burg ME, Loos WJ, Brouwer E, Viganò L, Locatelli A, de Vos AI, Nooter K, Stoter G, Gianni L.
    Clin Cancer Res; 1998 Aug 01; 4(8):1937-42. PubMed ID: 9717822
    [Abstract] [Full Text] [Related]

  • 5. Nonlinear pharmacokinetics of paclitaxel in mice results from the pharmaceutical vehicle Cremophor EL.
    Sparreboom A, van Tellingen O, Nooijen WJ, Beijnen JH.
    Cancer Res; 1996 May 01; 56(9):2112-5. PubMed ID: 8616858
    [Abstract] [Full Text] [Related]

  • 6. Dosing sequence-dependent pharmacokinetic interaction of oxaliplatin with paclitaxel in the rat.
    Liu J, Kraut EH, Balcerzak S, Grever M, D'Ambrosio S, Chan KK.
    Cancer Chemother Pharmacol; 2002 Dec 01; 50(6):445-53. PubMed ID: 12451470
    [Abstract] [Full Text] [Related]

  • 7. Disposition kinetics of taxanes after intraperitoneal administration in rats and influence of surfactant vehicles.
    Yokogawa K, Jin M, Furui N, Yamazaki M, Yoshihara H, Nomura M, Furukawa H, Ishizaki J, Fushida S, Miwa K, Miyamoto K.
    J Pharm Pharmacol; 2004 May 01; 56(5):629-34. PubMed ID: 15142340
    [Abstract] [Full Text] [Related]

  • 8. Linearized colorimetric assay for cremophor EL: application to pharmacokinetics after 1-hour paclitaxel infusions.
    Brouwer E, Verweij J, Hauns B, Loos WJ, Nooter K, Mross K, Stoter G, Sparreboom A.
    Anal Biochem; 1998 Aug 01; 261(2):198-202. PubMed ID: 9716422
    [Abstract] [Full Text] [Related]

  • 9. Measurement of fraction unbound paclitaxel in human plasma.
    Brouwer E, Verweij J, De Bruijn P, Loos WJ, Pillay M, Buijs D, Sparreboom A.
    Drug Metab Dispos; 2000 Oct 01; 28(10):1141-5. PubMed ID: 10997930
    [Abstract] [Full Text] [Related]

  • 10. Comparative in vitro properties and clinical pharmacokinetics of Paclitaxel following the administration of taxol(r) and paxene(r).
    Scripture CD, Szebeni J, Loos WJ, Figg WD, Sparreboom A.
    Cancer Biol Ther; 2005 May 01; 4(5):555-60. PubMed ID: 15917657
    [Abstract] [Full Text] [Related]

  • 11. Entrapment by Cremophor EL decreases the absorption of paclitaxel from the gut.
    Bardelmeijer HA, Ouwehand M, Malingré MM, Schellens J, Beijnen JH, van Tellingen O.
    Cancer Chemother Pharmacol; 2002 Feb 01; 49(2):119-25. PubMed ID: 11862425
    [Abstract] [Full Text] [Related]

  • 12. Cremophor EL causes (pseudo-) non-linear pharmacokinetics of paclitaxel in patients.
    van Tellingen O, Huizing MT, Panday VR, Schellens JH, Nooijen WJ, Beijnen JH.
    Br J Cancer; 1999 Sep 01; 81(2):330-5. PubMed ID: 10496361
    [Abstract] [Full Text] [Related]

  • 13. Inter-relationships of paclitaxel disposition, infusion duration and cremophor EL kinetics in cancer patients.
    van Zuylen L, Gianni L, Verweij J, Mross K, Brouwer E, Loos WJ, Sparreboom A.
    Anticancer Drugs; 2000 Jun 01; 11(5):331-7. PubMed ID: 10912949
    [Abstract] [Full Text] [Related]

  • 14. The co-solvent Cremophor EL limits absorption of orally administered paclitaxel in cancer patients.
    Malingré MM, Schellens JH, Van Tellingen O, Ouwehand M, Bardelmeijer HA, Rosing H, Koopman FJ, Schot ME, Ten Bokkel Huinink WW, Beijnen JH.
    Br J Cancer; 2001 Nov 16; 85(10):1472-7. PubMed ID: 11720431
    [Abstract] [Full Text] [Related]

  • 15. Disposition of [G-(3)H]paclitaxel and cremophor EL in a patient with severely impaired renal function.
    Gelderblom H, Verweij J, Brouwer E, Pillay M, de Bruijn P, Nooter K, Stoter G, Sparreboom A.
    Drug Metab Dispos; 1999 Nov 16; 27(11):1300-5. PubMed ID: 10534315
    [Abstract] [Full Text] [Related]

  • 16. Comparative preclinical and clinical pharmacokinetics of a cremophor-free, nanoparticle albumin-bound paclitaxel (ABI-007) and paclitaxel formulated in Cremophor (Taxol).
    Sparreboom A, Scripture CD, Trieu V, Williams PJ, De T, Yang A, Beals B, Figg WD, Hawkins M, Desai N.
    Clin Cancer Res; 2005 Jun 01; 11(11):4136-43. PubMed ID: 15930349
    [Abstract] [Full Text] [Related]

  • 17. Population pharmacokinetics of orally administered paclitaxel formulated in Cremophor EL.
    de Jonge ME, Huitema AD, Schellens JH, Rodenhuis S, Beijnen JH.
    Br J Clin Pharmacol; 2005 Mar 01; 59(3):325-34. PubMed ID: 15752379
    [Abstract] [Full Text] [Related]

  • 18. Pharmacokinetics, tissue distribution and anti-tumour efficacy of paclitaxel delivered by polyvinylpyrrolidone solid dispersion.
    Liu X, Sun J, Chen X, Wang S, Scott H, Zhang X, Zhang Q.
    J Pharm Pharmacol; 2012 Jun 01; 64(6):775-82. PubMed ID: 22571255
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.